Bioequivalence & Bioavailability

نویسندگان

  • Somruedee Chatsiricharoenkul
  • Suvimol Niyomnaitham
  • Piyapat Pongnarin
  • Korbtham Sathirakul
  • Supornchai Kongpatanakul
چکیده

The pharmacokinetics of olanzapine are linear and doseproportional within the approved dosage range from 1 mg up to 20 mg. Olanzapine is well absorbed following oral administration in both fed and fasted states . Food does not affect the rate or the extent of olanzapine absorption. Time of peak concentration ranges from 2-7 h [4,5]. Olanzapine is extensively distributed throughout the body, binding primarily to albumin (90%) and α1 -acid glycoprotein (77%). Olanzapine is eliminated extensively (40%) of the dose by first pass metabolism. Direct glucuronidation and CYP1A2 mediated oxidation are the primary metabolic pathways for olanzapine. Phenotypic difference for CYP1A2 between races has been reported. The pharmacokinetics of olanzapine are similar amongst Japanese, Chinese and Caucasians [6,7]. The most common adverse effects of olanzapine in patients receiving olanzapine in short term were weight gain, somnolence, postural hypotension, dizziness, constipation, dyspepsia, dry mouth, increased appetite, tremor, personality disorder, asthenia and akathisia [6,8].

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Bioequivalence and Bioavailability Clinical Trials: A Status Report from the National Institutes of Health ClinicalTrials.gov Registry

Drug development is an expensive process that is marked by a high-failure rate. For this reason early stage bioequivalence and pharmacokinetic studies are essential in determining the fate of new drug products. In this study, we sought to systematically assess the current trends of ongoing and recently completed bioequivalence and bioavailability trials that have been registered within a nation...

متن کامل

Evaluating average bioequivalence using methods for high variability drugs: a case study.

The purpose of this study was to determine if different methods for average bioequivalence in high variability drugs coincide or not in their conclusions when applied to the same dataset, and to discuss the method validity and reliability of the conclusions. Different approaches for the evaluation of average bioequivalence were applied to the results of a bioavailability trial on the diuretic d...

متن کامل

In vivo and In vitro Bioequivalence Testing

For approval of generic drug products, bioequivalence testing is considered as a surrogate for clinical evaluation of the therapeutic equivalence of drug products based on the Fundamental Bioequivalence Assumption that when two drug products (e.g., a brand-name drug and its generic copy) are equivalent in bioavailability, they will reach the same therapeutic effect. Although bioavailability for...

متن کامل

Comparative Bioavailability of Ranitidine Tablets in Healthy Volunteers

The pharmacokinetic parameters of domestic and imported ranitidine hydrochloride tablets (Ranitidine, formulated and manufactured by Kharazmi Pharmaceuticals, Iran, and Zantac ? manufactured by Glaxo, UK) were measured in 14 healthy subjects following oral administration of a single 300-mg dose of each brand and compared for bioequivalence evaluation. The pharmaceutical equivalency of both fo...

متن کامل

Are the current bioequivalence standards sufficient for the acceptance of narrow therapeutic index drugs? Utilization of a computer simulated warfarin bioequivalence model.

PURPOSE The purpose of this computer simulation was to determine the likelihood of two bioequivalent (vs. reference) generic warfarin formulations (with varying bioavailability) passing current bioequivalence criteria against each other at varying bioavailability. Methods. A bioequivalence simulation program generated 100 warfarin bioequivalence (BE) studies with 24 patients/study. The referenc...

متن کامل

Investigation of Bioavailability and Bioequivalence

Additional Notes This note for guidance concerns the application of Part 4, section E of the Annex to Directive 75/318/EEC as amended and Article 4,2 point 8 of Directive 65/65/EEC as amended with a view to the granting of a marketing authorisation for a medicinal product. It defines when bioavailability or bioequivalence studies are necessary for immediate release products with a systemic effe...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2011